Name: 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference (EST TIME ZONE)
Start: 2021-10-28
End: 2021-10-29

WHAT TO EXPECT

Cell culture through dimensional process
Lentiviral bioprocessing
Automation of cellular therapies
AAV vector production
Process development and monitoring of cell-gene therapies
CMC considerations for NK cells
Supply chain and regulatory issues

From Therapeutics and Pharmaceuticals, Cell & Gene therapy-based companies:
Engineers/Scientists/Researchers/Project leaders in: Bioprocess development,
Process development, GMP/Manufacturing, Cellular Therapy, Gene Therapy, Quality Control, Cell Engineering, Regulatory affairs

From Universities and Research Institutes:

Scientists/Professors/Researchers/Project leaders in: Bioprocessing, Bioengineering, Biomaterials, Chemical Engineering, Material Sciences, Cell therapy, Gene therapy, Cell culture, Cell Engineering, GMP/Manufacturing

CONFERENCE AGENDA

Online registrations	08:30 - 08:45
Opening note by MarketsandMarkets	08:45 - 08:50
Opening remark by chairperson	08:50 - 09:00
Personalized tissue-engineered organs that will revolutionize future medicine Petter Bjorquist, CEO, Verigraft	09:00 - 09:30
Cell therapy: new frontiers and new challenges Prasun Mishra, Founding Director, Chairman of the Board, Agility Pharmaceuticals	09:30 - 10:00
How to monitor protein impurities to ensure consistent gene therapy products Ejvind Mortz, Chief Operating Officer, Alphalyse	10:00 - 10:30
Networking break	10:30 - 10:40
Over coming autologous manufacturing by adaptive culturing. Metabolic and environmental control-based automation, machine learning and IA with the Adva X3 Ohad Karneili, Founder & CEO, Adva Biotechnology	10:40 - 11:10
CELL-GENE THERAPY PROCESS DEVELOPMENT AND ANALYTICS
Variable starting material, variable product, striving for consistency in cell-based therapeutics William Janssen, Consultant, Cell & Gene Therapy Consulting LLC	11:10 - 11:40
High-throughput, automated analysis of viral vector titer and process related impurities accelerates downstream process development of AAV based gene therapies Maria Germana Sanna, Field Application Scientist, Gyros Protein Technologies	11:40 - 12:10
Cell and gene therapy manufacturing process control Scott Burger, Principal, Advanced Cell & Gene Therapy LLC	12:10 - 12:40
Closing Remarks	12:40 - 12:45
Networking	12:45 - 13:15
End of day 1	13:15 - 13:15

Online Registrations	08:30 - 08:45
Opening note by MarketsandMarkets	08:45 - 08:50
Opening remark by chairperson	08:50 - 09:00
Manufacturing Platforms and Considerations for Adeno-associated viral vector based Gene Therapy Products Hemant Dhamne , Head of Vector and CAR-T Cell Processing, Immuneel Therapeutics Pvt Ltd	09:00 - 09:30
CAR-T in a Mirror : how innovation & Development (I&D) make them look better Stefano Baila, Director of Operations & Business Development, Anemocyte	09:30 - 10:00
Big solutions come in small Packages: Expanding sterile connection technology to small-format product or process fluid volume transfer applications Jayanthi Grebin, Senior Business Development Manager, Cell & Gene Therapy , CPC	10:00 - 10:15
Networking	10:15 - 10:30
Safety and quality of plasmids used in AAV viral vector production Audrey Chang, Vice President , QC & Analytical Development, Vigene Biosciences-A Charles River Company	10:30 - 11:00
Innovative product that integrate automation, software, precision mechanics and cooling systems at cryogenic temperatures (up to -180°C) Daniele Pericolini, Senior Product Manager & Application Scientist, Angelantoni Life Science S.r.l.	11:00 - 11:30
Next Generation Cell and Gene Therapies -> Raw Material and Supply Chain Considerations Tiffany Rau, Global Leader in Process Development (R &D, CMC), Manufacturing, & Commercialization-, Biotechnology, Biopharmaceuticals	11:30 - 12:00
Closing remarks	12:00 - 12:05
End of Conference	12:05 - 12:05